Title |
Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses
|
---|---|
Published in |
Vaccine, June 2014
|
DOI | 10.1016/j.vaccine.2014.06.049 |
Pubmed ID | |
Authors |
Pavla Simerska, Tittaya Suksamran, Zyta Maria Ziora, Fabian de Labastida Rivera, Christian Engwerda, Istvan Toth |
Abstract |
The lipid core peptide (LCP) system has successfully been used in development of peptide-based vaccines against cancer and infectious diseases (such as group A streptococcal infection). CD8(+) T cells are important targets for vaccines, however developing a vaccine that activates long-lasting immunity has proven challenging. The ability of LCP vaccines to activate antigen-specific CD8(+) and/or CD4(+) T cell responses was tested using compounds that contained two or four copies of OVA257-264 and/or OVA323-339 peptides conjugated to LCP, which are recognised by OTI (CD8(+) specific) and OTII (CD4(+) specific) T cells, respectively. The LCP-ovalbumin vaccines developed in this study were synthesised in 30% yields and showed no significant haemolytic effect on red blood cells (below 4% haemolysis when tested with compounds at up to 100μM concentrations). Promising in vivo data in mice suggested that this LCP-ovalbumin vaccine system could act as a novel and potent vehicle for the stimulation of robust antigen-specific CD8(+) T cell responses. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 35% |
Student > Master | 3 | 13% |
Lecturer | 2 | 9% |
Student > Bachelor | 2 | 9% |
Researcher | 2 | 9% |
Other | 2 | 9% |
Unknown | 4 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 13% |
Chemistry | 3 | 13% |
Immunology and Microbiology | 3 | 13% |
Biochemistry, Genetics and Molecular Biology | 2 | 9% |
Engineering | 2 | 9% |
Other | 5 | 22% |
Unknown | 5 | 22% |